看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
6 N+ S1 ]4 r* @0 X. S0 m8 q8 @' K; `' ]8 A4 d
8 T2 ?; _: M+ ~/ {6 W
Currently available feasibility data for possible combination strategies. - y0 N# s$ R( u: G9 S5 ~9 }3 u) J$ ~9 f
————————————————————————————————
# Z I% Q6 J, {2 F8 eCombination Feasibility according to preliminary data 6 t0 w' E7 g. {4 G% j1 j
——————————————————————————————————( H$ n- @. e. ^5 Y, l! f' H
Bevacizumab + sorafenib Yes, reduced dose
: n* V6 L$ i6 C: W4 YBevacizumab + sunitinib† No
( g; ?1 j9 J( V6 ABevacizumab + temsirolimus Yes
9 ]: g* p3 M1 E" C5 l8 w% JBevacizumab + everolimus Yes
z, O, f( s9 ^Sorafenib + sunitinib ?
+ Z; ^* D6 @) C& z2 @6 pSorafenib + temsirolimus Yes, reduced dose
6 o( @- m5 N8 |# {) vSorafenib + everolimus Yes, reduced dose 6 K# s; @8 y% T: I
Sunitinib + temsirolimus† No
3 G* Z6 {) S; d$ ]+ G% FSunitinib + everolimus ?
3 k6 i. f5 X6 ~9 d# }* mTemsirolimus + everolimus ? $ d6 `9 P3 i- t- ^/ a: ]* j
———————————————————— C" ]8 }8 b6 R" F# y* y7 F* z
†Led to US FDA warning./ K3 Y# @, i6 d0 |5 H
?: As yet unattempted combination." `9 G9 l7 R4 g- L0 X1 m; f& c
|